These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

419 related items for PubMed ID: 20014178

  • 1. Muscle toxicity with statins.
    Hedenmalm K, Alvan G, Ohagen P, Dahl ML.
    Pharmacoepidemiol Drug Saf; 2010 Mar; 19(3):223-31. PubMed ID: 20014178
    [Abstract] [Full Text] [Related]

  • 2. The risk for significant creatine kinase elevation with statins.
    Stolcpart RS, Olson KL, Delate T, Rasmussen J, Rehring TF, Merenich JA.
    Am J Cardiovasc Drugs; 2010 Mar; 10(3):187-92. PubMed ID: 20524720
    [Abstract] [Full Text] [Related]

  • 3. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy.
    Chang JT, Staffa JA, Parks M, Green L.
    Pharmacoepidemiol Drug Saf; 2004 Jul; 13(7):417-26. PubMed ID: 15269925
    [Abstract] [Full Text] [Related]

  • 4. Managing statin-induced muscle toxicity in a lipid clinic.
    Blaier O, Lishner M, Elis A.
    J Clin Pharm Ther; 2011 Jun; 36(3):336-41. PubMed ID: 21414023
    [Abstract] [Full Text] [Related]

  • 5. The risk of myopathy associated with thiazolidinediones and statins in patients with type 2 diabetes: a nested case-control analysis.
    Koro CE, Sowell MO, Stender M, Qizilbash N.
    Clin Ther; 2008 Mar; 30(3):535-42. PubMed ID: 18405791
    [Abstract] [Full Text] [Related]

  • 6. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy.
    Silva M, Matthews ML, Jarvis C, Nolan NM, Belliveau P, Malloy M, Gandhi P.
    Clin Ther; 2007 Feb; 29(2):253-60. PubMed ID: 17472818
    [Abstract] [Full Text] [Related]

  • 7. Should high creatine kinase discourage the initiation or continuance of statins for the treatment of hypercholesterolemia?
    Glueck CJ, Rawal B, Khan NA, Yeramaneni S, Goldenberg N, Wang P.
    Metabolism; 2009 Feb; 58(2):233-8. PubMed ID: 19154957
    [Abstract] [Full Text] [Related]

  • 8. Differential association between statin exposure and elevated levels of creatine kinase.
    Chan J, Hui RL, Levin E.
    Ann Pharmacother; 2005 Oct; 39(10):1611-6. PubMed ID: 16160000
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Risk factors for statin-associated rhabdomyolysis.
    Schech S, Graham D, Staffa J, Andrade SE, La Grenade L, Burgess M, Blough D, Stergachis A, Chan KA, Platt R, Shatin D.
    Pharmacoepidemiol Drug Saf; 2007 Mar; 16(3):352-8. PubMed ID: 16892458
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Estimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysis.
    McAdams M, Staffa J, Dal Pan G.
    Pharmacoepidemiol Drug Saf; 2008 Mar; 17(3):229-39. PubMed ID: 18175291
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Creatine kinase increase under simvastatin--therapeutic consequences?].
    Rasche-Schürmann CC, Picksak G, Stichtenoth DO.
    Med Monatsschr Pharm; 2008 Jan; 31(1):25-7. PubMed ID: 18522017
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Rhabdomyolysis in association with simvastatin and amiodarone.
    Roten L, Schoenenberger RA, Krähenbühl S, Schlienger RG.
    Ann Pharmacother; 2004 Jun; 38(6):978-81. PubMed ID: 15069169
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.